Iterum Therapeutics PLC (NASDAQ:ITRM) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 95,100 shares, a growth of 22.7% from the September 30th total of 77,500 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily volume of 25,200 shares, the days-to-cover ratio is presently 3.8 days.
ITRM has been the subject of several recent research reports. Zacks Investment Research lowered Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 25th. ValuEngine raised Iterum Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Iterum Therapeutics in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $15.75.
ITRM stock traded down $0.27 on Thursday, reaching $2.14. The company’s stock had a trading volume of 69,000 shares, compared to its average volume of 14,600. Iterum Therapeutics has a 52 week low of $1.89 and a 52 week high of $9.30. The company has a market capitalization of $32.11 million, a P/E ratio of -0.30 and a beta of 1.82. The firm has a fifty day moving average of $3.99 and a two-hundred day moving average of $6.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10.
Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.54). Iterum Therapeutics had a negative return on equity of 136.21% and a negative net margin of 11,956.64%. As a group, equities analysts expect that Iterum Therapeutics will post -6.82 EPS for the current fiscal year.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Read More: What is the market perform rating?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.